WallStreetZen

NASDAQ: HCAT
Health Catalyst Inc Stock Forecast, Predictions & Price Target

Analyst price target for HCAT

Based on 4 analysts offering 12 month price targets for Health Catalyst Inc.
Min Forecast
$60.00+10.95%
Avg Forecast
$65.50+21.12%
Max Forecast
$70.00+29.44%

Should I buy or sell HCAT stock?

Based on 4 analysts offering ratings for Health Catalyst Inc.
Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

HCAT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Raymond James
Top 8%
93
Strong BuyMaintains$70.00+29.44%2021-08-10
Citigroup
Top 18%
83
Strong BuyMaintains$68.00+25.74%2021-08-09
SVB Leerink
Top 15%
86
BuyMaintains$64.00+18.34%2021-08-06
Anonymous
Goldman Sachs
Strong BuyMaintains$60.00+10.95%2021-05-07

1 of 1

Forecast return on equity

Is HCAT forecast to generate an efficient return?
Company
-25.76%
Industry
12.31%
Market
60.49%
HCAT's Return on Equity is forecast to be low in 3 years (-25.76%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is HCAT forecast to generate an efficient return on assets?
Company
-12.62%
Industry
7.14%
Market
16.9%
HCAT is forecast to generate lower Return on Assets (-12.62%) than the US Health Information Services industry average (7.14%)
Forecast

HCAT earnings per share forecast

What is HCAT's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
-$1.83-42.43%
Avg 2 year Forecast
-$1.73-45.58%
Avg 3 year Forecast
-$1.53-51.89%

HCAT revenue forecast

What is HCAT's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$238.9M+10.63%
Avg 2 year Forecast
$290.9M+34.72%
Avg 3 year Forecast
$355.2M+64.47%
HCAT's revenue is forecast to grow at a rate of 16.82% per year, which is not exceptional
Forecast

HCAT revenue growth forecast

How is HCAT forecast to perform vs Health Information Services companies and vs the US market?
Company
16.82%
Industry
15.67%
Market
14.3%
HCAT's revenues are forecast to grow faster (16.82% per year) than the US Health Information Services industry average (15.67%)
Forecast
HCAT's revenues are forecast to grow faster (16.82% per year) than the US market average (14.3%)
Forecast

Health Catalyst Stock Forecast FAQ

Is Health Catalyst Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: HCAT) stock is to Strong Buy HCAT stock.

Out of 4 analysts, 3 (75%) are recommending HCAT as a Strong Buy, 1 (25%) are recommending HCAT as a Buy, 0 (0%) are recommending HCAT as a Hold, 0 (0%) are recommending HCAT as a Sell, and 0 (0%) are recommending HCAT as a Strong Sell.

What is HCAT's earnings growth forecast for 2021-2023?

(NASDAQ: HCAT) Health Catalyst's forecast annual earnings growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 27.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.36%.

Health Catalyst's earnings in 2021 is -$134,548,000.On average, 6 Wall Street analysts forecast HCAT's earnings for 2021 to be $-85,050,064, with the lowest HCAT earnings forecast at $-89,477,328, and the highest HCAT earnings forecast at $-78,292,662. On average, 2 Wall Street analysts forecast HCAT's earnings for 2022 to be $-80,389,787, with the lowest HCAT earnings forecast at $-89,011,300, and the highest HCAT earnings forecast at $-71,768,274.

In 2023, HCAT is forecast to generate $-71,069,232 in earnings, with the lowest earnings forecast at $-73,632,385 and the highest earnings forecast at $-68,506,079.

What is HCAT's revenue growth forecast for 2021-2023?

(NASDAQ: HCAT) Health Catalyst's forecast annual revenue growth rate of 16.82% is forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 15.67%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 14.3%.

Health Catalyst's revenue in 2021 is $215,943,000.On average, 6 Wall Street analysts forecast HCAT's revenue for 2021 to be $11,133,402,948, with the lowest HCAT revenue forecast at $11,049,051,925, and the highest HCAT revenue forecast at $11,227,633,759. On average, 6 Wall Street analysts forecast HCAT's revenue for 2022 to be $13,557,120,070, with the lowest HCAT revenue forecast at $13,342,840,510, and the highest HCAT revenue forecast at $13,831,703,620.

In 2023, HCAT is forecast to generate $16,552,000,802 in revenue, with the lowest revenue forecast at $15,822,900,387 and the highest revenue forecast at $17,084,577,315.

What is HCAT's forecast return on assets (ROA) for 2021-2023?

(NASDAQ: HCAT) forecast ROA is -12.62%, which is lower than the forecast US Health Information Services industry average of 7.14%.

What is HCAT's Price Target?

According to 4 Wall Street analysts that have issued a 1 year HCAT price target, the average HCAT price target is $65.50, with the highest HCAT stock price forecast at $70.00 and the lowest HCAT stock price forecast at $60.00.

On average, Wall Street analysts predict that Health Catalyst's share price could stay at $65.50 by Aug 10, 2022. The average Health Catalyst stock price prediction forecasts a potential downside of N/A from the current HCAT share price of $54.08.

What is HCAT's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: HCAT) Health Catalyst's current Earnings Per Share (EPS) is -$3.17. On average, analysts forecast that HCAT's EPS will be $-1.83 for 2021, with the lowest EPS forecast at $-1.92, and the highest EPS forecast at $-1.68. On average, analysts forecast that HCAT's EPS will be $-1.73 for 2022, with the lowest EPS forecast at $-1.91, and the highest EPS forecast at $-1.54. In 2023, HCAT's EPS is forecast to hit $-1.53 (min: $-1.58, max: $-1.47).

What is HCAT's forecast return on equity (ROE) for 2021-2023?

(NASDAQ: HCAT) forecast ROE is -25.76%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.